| 000 | 01874 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517013730.0 | ||
| 264 | 0 | _c20150414 | |
| 008 | 201504s 0 0 eng d | ||
| 022 | _a1520-4804 | ||
| 024 | 7 |
_a10.1021/jm501722s _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHuleatt, Paul B | |
| 245 | 0 | 0 |
_aNovel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease. _h[electronic resource] |
| 260 |
_bJournal of medicinal chemistry _cFeb 2015 |
||
| 300 |
_a1400-19 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMolecular Structure |
| 650 | 0 | 4 |
_aMonoamine Oxidase _xmetabolism |
| 650 | 0 | 4 |
_aMonoamine Oxidase Inhibitors _xchemical synthesis |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xchemical synthesis |
| 650 | 0 | 4 | _aPC12 Cells |
| 650 | 0 | 4 |
_aPargyline _xanalogs & derivatives |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aPropylamines _xchemical synthesis |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aKhoo, Mui Ling | |
| 700 | 1 | _aChua, Yi Yuan | |
| 700 | 1 | _aTan, Tiong Wei | |
| 700 | 1 | _aLiew, Rou Shen | |
| 700 | 1 | _aBalogh, Balázs | |
| 700 | 1 | _aDeme, Ruth | |
| 700 | 1 | _aGölöncsér, Flóra | |
| 700 | 1 | _aMagyar, Kalman | |
| 700 | 1 | _aSheela, David P | |
| 700 | 1 | _aHo, Han Kiat | |
| 700 | 1 | _aSperlágh, Beáta | |
| 700 | 1 | _aMátyus, Péter | |
| 700 | 1 | _aChai, Christina L L | |
| 773 | 0 |
_tJournal of medicinal chemistry _gvol. 58 _gno. 3 _gp. 1400-19 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/jm501722s _zAvailable from publisher's website |
| 999 |
_c24571030 _d24571030 |
||